Chondrosamine capsules 200 mg 250 mg packaging No. 60
Chondrosamine Trade name of the drug: Chondrosamine Dosage form: capsules.
Composition: one capsule contains chondroitin sulfate - 200 mg; glucosamine hydrochloride - 250 mg. Excipients: magnesium stearate, lactose. Composition of the capsule shell: gelatin, glycerin, purified water, titanium dioxide E-171, sodium lauryl sulfate, dye: sunset yellow E - 110.
Description. Hard gelatin capsules No. 0 are cylindrical in shape with hemispherical ends with a white body and an orange cap.
Pharmacotherapeutic group: Other drugs for the treatment of diseases of the musculoskeletal system. ATX code M09AX.
Indications for use Chondrosamine is used: - as an additional means to relieve pain in arthrosis of the hip or knee; - for symptomatic treatment of the consequences of arthrosis of the knee and hip joints; — in the complex treatment of degenerative-dystrophic diseases of the spine (including osteochondrosis).
Method of administration and dosage Adults and children over 15 years of age take orally with a small amount of water, at the beginning of treatment - 2 capsules 2-4 times a day, after a month of treatment the dose can be reduced to 2 capsules 1-2 times a day. The optimal dosage regimen is determined by the doctor. Duration of treatment is 1.5-3 months. A stable therapeutic effect is achieved when taken for at least 6 months.
Side effects Can be observed in case of overdose or increased individual sensitivity to the ingredients of the drug: gastrointestinal dysfunction (nausea, epigastric pain, flatulence, diarrhea/constipation), dizziness, allergic skin reactions.
Cautions Do not exceed the dose recommended by your doctor. Interactions with other drugs When used in combination, it enhances the absorption of tetracyclines from the gastrointestinal tract and reduces penicillins and chloramphenicol. Compatible with NSAIDs and glucocorticoids. While taking it, the need for non-steroidal anti-inflammatory drugs decreases.
Contraindications: Increased individual sensitivity to any of the components of the drug (allergic reactions), phenylketonuria, severe renal impairment, children under 15 years of age. Contraindicated during pregnancy and breastfeeding.
Impact on the ability to drive a car, work with equipment. No effect.
Release form: Hard gelatin capsules No. 0, cylindrical in shape with hemispherical ends, white body and orange cap, 10 capsules per blister, 6 blisters per pack.
Storage conditions Store in a place protected from moisture and light at a temperature of 15C to 25C.
Shelf life: 2 years. Do not use after the expiration date stated on the packaging. The release is made without a doctor's prescription.
Instructions for use CHONDROSAMINE NEO
Inducers of microsomal oxidation (phenytoin, ethanol, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants) increase the production of hydroxylated active metabolites, increasing the risk of severe hepatotoxic reactions.
Microsomal oxidation inhibitors reduce the risk of hepatotoxicity.
The drug reduces the hypotensive effect of vasodilators (including slow calcium channel blockers and ACE inhibitors).
The drug reduces the natriuretic and diuretic activity of furosemide and hydrochlorothiazide.
Reduces the effectiveness of uricosuric drugs.
Strengthens the effect of indirect anticoagulants, antiplatelet agents, fibrinolytics (increasing the risk of hemorrhagic complications).
Strengthens the ulcerogenic effect (with the development of bleeding) of GCS, NSAIDs, colchicine, estrogens, ethanol.
Enhances the effect of oral hypoglycemic drugs and insulin.
Antacids and cholestyramine reduce the absorption of ibuprofen.
Increases the blood concentration of digoxin, lithium and methotrexate.
Caffeine enhances the analgesic effect of Chondrosamine Neo.
When administered simultaneously, ibuprofen reduces the anti-inflammatory and antiplatelet effect of acetylsalicylic acid (it is possible to increase the incidence of acute coronary insufficiency in patients receiving small doses of acetylsalicylic acid as an antiplatelet agent after starting ibuprofen).
When prescribed with anticoagulant and thrombolytic drugs (alteplase, streptokinase, urokinase), the risk of bleeding simultaneously increases.
Cefamandole, cefoperazone, cefotetan, valproic acid, plicamycin increase the incidence of hypoprothrombinemia.
Myelotoxic drugs increase the manifestations of hematotoxicity.
Cyclosporine and gold preparations enhance the effect of ibuprofen on the synthesis of prostaglandins in the kidneys, which is manifested by increased nephrotoxicity.
Ibuprofen increases the plasma concentration of cyclosporine and the likelihood of developing its hepatotoxic effects.
Drugs that block tubular secretion reduce excretion and increase plasma concentrations of ibuprofen.
Due to the glucosamine content in the drug, the effectiveness of hypoglycemic drugs, doxorubicin, teniposide, and etoposide may be reduced.
Glucosamine increases the absorption of tetracyclines and reduces the effect of semisynthetic penicillins and chloramphenicol.
Chondrosamine Neo capsules No. 10x6
Name
Description
Hard gelatin capsules of cylindrical shape with hemispherical ends with a white body and a red-brown cap.
Main active ingredient
Chondroitin sulfate + glucosamine + ibuprofen
Release form
Capsules
Dosage
60 pcs.
Indications for use
For short-term relief of pain and other symptoms of inflammation during exacerbation of osteoarthritis, osteoarthritis, degenerative diseases of the knee and hip joints and spine.
Directions for use and doses
Adults take 1-2 capsules 2-3 times a day after meals. Capsules are taken orally with a small amount of water. The maximum duration of treatment should not exceed 20 days. After the severe pain has reduced, the patient can continue treatment with combination agents containing glucosamine hydrochloride and chondroitin sulfate.
Use during pregnancy and lactation
Use is contraindicated. Fertility: There is evidence that drugs that inhibit cyclooxygenase/prostaglandin synthesis can adversely affect the reproductive capacity of women by affecting the ovulation process. After discontinuation of use, this effect is reversible.
Precautionary measures
Patients with a known seafood allergy are advised to take Chondrosamine Neo with caution. Glucosamine hydrochloride Before use, you should consult your doctor to rule out joint diseases for which other treatment methods are prescribed. In patients with impaired glucose tolerance, monitoring of blood glucose levels is necessary and, if necessary, it is recommended to determine the need for insulin before starting treatment and periodically during treatment. In patients with known risk factors for cardiovascular disease, it is recommended to monitor blood lipid levels, as hypercholesterolemia has been observed in some cases in patients treated with glucosamine. Exacerbation of asthma symptoms following administration of glucosamine has been reported (symptoms resolved shortly after discontinuation of glucosamine administration). Patients with asthma should be aware of the possible worsening of symptoms. Use the drug with caution for bronchial asthma and diabetes. When using the drug in patients with impaired glucose tolerance, severe liver and kidney failure, medical supervision is necessary. Ibuprofen Gastrointestinal precautions: Avoid using Chondrosamine Neo with non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors. The occurrence of side effects can be minimized by using the lowest effective dose for the shortest duration of use necessary to improve the condition. Elderly Patients Elderly patients are particularly prone to developing side effects from NSAIDs and close monitoring is recommended. Gastrointestinal bleeding, peptic ulcers, and ulcer perforation Gastrointestinal bleeding, ulcers, or ulcer perforation, potentially life-threatening, have been reported during treatment with NSAIDs, with or without warning symptoms. , and also regardless of the presence of severe pathology of the gastrointestinal tract in the anamnesis. The risk of developing gastrointestinal bleeding, ulcer formation, or perforation increases with increasing doses of NSAIDs in patients with a history of peptic ulcer disease, especially complicated by bleeding or perforation, as well as in elderly patients. Treatment of these patients should be started with the lowest possible dose. For these patients, as well as patients who require concomitant therapy with low-dose aspirin or other drugs that increase the risk of gastrointestinal disorders, combination therapy with drugs that have a protective effect (for example, misoprostol or inhibitors) should be considered. proton pump). Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (in particular gastrointestinal bleeding), especially during the initial stages of treatment. When taken concomitantly with drugs that may increase the risk of ulcers or bleeding, extreme caution should be exercised. These medications include oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors, or antiplatelet agents such as aspirin. If gastrointestinal bleeding or ulcers occur when using the drug Chondrosamine Neo, treatment with the drug must be stopped. NSAIDs, which include ibuprofen, should be prescribed with caution to patients with a history of gastrointestinal diseases (ulcerative colitis, Crohn's disease), as they can cause exacerbation of these diseases. Effects on the cardiovascular system and cerebral circulation The drug should be prescribed with caution to patients with arterial hypertension and/or heart failure in history (consultation with a doctor or pharmacy is required), since during the treatment of NSAIDs there have been cases of fluid retention in the tissues, arterial hypertension and development of edema. Based on clinical trials and epidemiological data, the use of ibuprofen, especially in high doses (2400 mg per day), as well as during long-term therapy, may be associated with a slight increase in the risk of developing conditions caused by arterial thrombosis (for example, myocardial infarction or stroke). In general, evidence from epidemiological studies suggests that low doses of ibuprofen (e.g.
Interaction with other drugs
Glucosamine hydrochloride is compatible with non-steroidal anti-inflammatory drugs, paracetamol and glucocorticosteroids. An increase in thrombosis time has been reported with coumarin anticoagulants (eg, warfarin and acetocoumarol). Therefore, in patients receiving coumarin anticoagulants, it is necessary to carefully monitor the initiation and termination of glucosamine therapy. Concurrent treatment with glucosamine may increase the absorption and serum concentrations of tetracycline, but the clinical significance of this interaction is unlikely. Chondrosamine sulfate. Interactions not described. Ibuprofen (like other NSAIDs) requires special caution when taken with the following medications: Other NSAIDs, including salicylates: Concomitant use of several different NSAIDs may increase the risk of gastrointestinal ulcers and bleeding due to a synergistic effect. In this regard, the simultaneous use of ibuprofen and other NSAIDs is not recommended. Digoxin, phenytoin, lithium: the use of the drug Chondrosamine Neo simultaneously with digoxin, phenytoin or lithium may increase the concentration of these drugs in plasma. Monitoring the concentrations of lithium, digoxin and phenytoin in plasma when used correctly is usually not required (maximum within 4 days). Diuretics, ACE inhibitors, beta blockers and angiotensin II antagonists: NSAIDs may reduce the effectiveness of diuretics and other antihypertensive agents. In some patients with impaired renal function (for example, in dehydrated patients or in elderly patients with limited renal function), co-administration of ACE inhibitors, beta blockers or angiotensin II antagonists, as well as substances that inhibit the cyclooxygenase system, may cause further decrease in kidney function (up to acute renal failure), which is usually reversible. Therefore, the combined use of these drugs should be prescribed with caution, especially in elderly patients. Patients should receive sufficient fluids. Renal function should be periodically monitored closely both after initiation of co-therapy and subsequently. When taking ibuprofen and potassium-sparing diuretics simultaneously, hyperkalemia may develop. Corticosteroids: Increased risk of developing gastrointestinal ulcers or bleeding. Platelet aggregation inhibitors and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding. Acetylsalicylic acid in small doses: Experimental data suggest that when used concomitantly with ibuprofen, an inhibitory effect on the effect of low doses of acetylsalicylic acid on platelet aggregation may be observed. However, insufficient data and existing doubts regarding the applicability of findings from ex vivo studies to the clinical setting suggest that no definitive conclusions can be drawn for regular ibuprofen use and that any clinically significant effects are considered unlikely for non-regular use. . Methotrexate: Taking ibuprofen within 24 hours before and after taking methotrexate may lead to increased concentrations of methotrexate and increased toxicity. Cyclosporine: Concomitant use of certain NSAIDs increases the risk of renal dysfunction due to the effects of cyclosporine. The appearance of this effect is not excluded when cyclosporine is combined with ibuprofen. Anticoagulants: NSAIDs may enhance the effect of anticoagulants such as warfarin. Sulfonylureas: The results of clinical studies indicate the presence of interactions between NSAIDs and antidiabetic drugs (sulfonylureas). Although the interaction of ibuprofen with sulfonylureas has not yet been described, it is recommended to monitor blood sugar levels when taking these drugs simultaneously for preventive purposes. Tacrolimus: Concomitant use increases the risk of nephrotoxicity. Zidovudine: There is evidence that the simultaneous use of zidovudine and ibuprofen in HIV-infected patients with hemophilia increases the risk of developing hemarthrosis and hematomas. Probenecid and sulfinpyrazone: Medicines containing probenecid and sulfinpyrazone may delay the elimination of ibuprofen from the body.
Contraindications
Hypersensitivity to any of the active or auxiliary substances; a history of bronchospasm, asthma, rhinitis or urticaria after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs); hematopoietic disorders of unknown origin; current or past history of recurrent peptic ulcer/bleeding (two or more separate episodes of confirmed peptic ulcer disease or bleeding); a history of gastrointestinal bleeding or ulcer perforation associated with previously prescribed NSAID therapy; cerebrovascular bleeding or other bleeding currently present; severe impairment of liver or kidney function (creatinine clearance
Compound
One capsule contains chondroitin sulfate - 200 mg; glucosamine hydrochloride - 250 mg, ibuprofen - 100.0 mg. Excipients: crospovidone (type A), colloidal anhydrous silicon dioxide, magnesium stearate, microcrystalline cellulose. Capsule shell composition: gelatin, glycerin, purified water, titanium dioxide E-171, sodium lauryl sulfate, dyes: charming red E-129, quinoline yellow E-104, brilliant blue E-133.
Overdose
For glucosamine hydrochloride and chondroitin sulfate, overdose symptoms are unknown. In case of established overdose, treatment is symptomatic. Ibuprofen. Symptoms of overdose: disorders of the nervous system - headache, dizziness, lightheadedness and loss of consciousness (with myoclonic convulsions in children), as well as abdominal pain, nausea and vomiting. The development of gastrointestinal bleeding, as well as functional disorders of the liver and kidneys is possible. Decreased blood pressure, respiratory depression and cyanosis are also possible. Therapeutic measures for overdose. There is no specific antidote for ibuprofen. Treatment depending on the degree, level and clinical symptoms of intoxication in accordance with generally accepted practice in intensive care.
Side effect
The frequency of adverse reactions listed below was determined using the following notation: very common (≥ 1/10), common (≥ 1/100 -
Storage conditions
Buy Chondrosamine Neo caps. in container pack No. 10x6 in the pharmacy
Price for Chondrosamine Neo caps. in container pack No. 10x6
Instructions for use for Chondrosamine Neo caps. in a container pack No. 10x6